10 September 2018

-
SciLifeLab

Hosted by:
SciLifeLab

View session Description
SciLifeLab - A National Resource for Life Science

Satellite Symposium

10:00 - 15:00Aula Medica

SciLifeLab (Science for Life Laboratory) is Sweden’s national center for molecular biosciences, with the mission to provide a unique and enabling infrastructure to the life science community, facilitate internationally leading collaborative science, and promote the translation of biomolecular research findings into lasting societal benefits.

As part of the Nordic Life Science Days 2018, we invite you to attend a one-day satellite symposium to learn more about SciLifeLab, meet our facilities, investigate our capabilities and technologies, and further develop how your organization can leverage this unique asset in Sweden’s life science sector.

The symposium is free of charge and exclusive for registered participants of NLSDays. If you have not yet registered for NLSDays, please visit www.nlsdays.com. The event is held in Aula Medica at Karolinska Institutet on Monday 10 September 2018, between 10:00–15:00. Bus service round trip from Stockholm Waterfront will be provided.

Welcome to sign up now at: 

www.scilifelab.se/events/scilifelab-nls

Umeå Biotech Incubator
Pfizer

Sponsored by:
Umeå Biotech Incubator
Pfizer

View session Description
The Best Nordic Startups' Competition

Startup Challenge @ NLSDays 2018

18:00 - 19:30Exhibition Hall - Level 4

Get ready to pitch!

Now is your chance to make a lasting first impression and establish yourself and your company with the Nordic region’s foremost investors. Prepare your 1-minute video pitch and fill in your Startup Challenge application today!

What?

Startup Challenge at Nordic Life Science Days, NLSDays, at Waterfront in Stockholm, evening of the 10th of September. This year Umeå Biotech Incubator will be hosting the event with Pfizer as sponsor.

How? 

Startup Challenge is an enjoyable pitching event showcasing the best and brightest startups currently emerging from the nordic life science ecosystem. Based on your video contributions, the best 12 will be selected to pitch live in front of hundreds of life science industry investors. It means that you will be pitching in front of a qualified audience. The winner receives a free admission with company presentation to the Nordic Life Science Days 2019.

Why?

Benefit from the ideal environment for your company to engage with the leaders in life science, NLSDays being an excellent opportunity to interact with people who have a successful track record and a great place to meet potential investors and partners. On the top of that, it will be fun! You will also get exposure through the website and the program for the conference.

What to do? 

Apply for Startup Challenge@NLSDays here

Checkpoints before you fill in your application

  • Your company has not participated in last year’s Startup Challenge @NLSDays (the pitch contest)
  • Your company is not older than 8 years (counting form official registration).
  • Your company have not attracted more than 2 million Euro in total financing.
  • Your company is a privately-owned company.
  • Your company is registered in one of the Nordic countries (Sweden, Denmark, Norway, Finland or Iceland).
  • Your company must be active within life science (pharma, medtech/diagnosics, E-health or other).
  • Your company has not attended any previous Startup Challenge @NLSDays (the pitch contest).
  • Your company has a representative who is available to attend the event on the 10th of September 2018 at Waterfront Stockholm if your company are selected for the live pitch final.

…If everything is in order, good! Now, follow these instructions:

  • Record your 1-minute video pitch. (You don’t need an advanced video camera, just take your smartphone and find a light room to record your pitch).
  • Upload your video on YouTube, Vimeo or other publicly available streaming site.
  • Fill in your application and upload the URL to your video here.

Great! Now you’re in the running towards becoming the next winner of the Startup Challenge 2018. Good luck!

Competition criteria and setup
The jury who consist of selected and experienced investors will give every video pitch score on a scale 1-7 based on these following judgement criteria:

  • Need: globally for patient/healthcare and market potential
  • Team: competence within the team
  • Approach: technical solution
  • Business model: how to earn money
  • Competition: competitions on the market and in pipe line
  • Final: How much money is needed, time period and what is going to be performed during that time. Exit for investors (when and how)

The 12 cases with the highest points will go to the finals and get to live pitch in front on hundreds important investors at NLSDays Startup Challenge 10th of September.

The live pitch must be 2 minutes long and the audience at the Startup Challenge at NLSDays will decide on site through live digital voting who the winner is, so it’s important to capture the audience! The winner will be announced on stage by a representative from Pfizer.

1st prize
The lucky winner of the Startup Challenge 2018 will receive a free entrance to NLSdays 2019 + a free company presentation. That’s huge!

Everyone is a winner!
All Startup Challenge applicants will get registration discounts for the entrance to NLSdays 2018.
For all Startup Challenge applicants (not selected for the finals but has fulfil the application criteria):

  • 15% discount on Small Company rate for those interested in attending the all-conference
  • 6,375 SEK + 25% VAT until May 31, 2018
  • 8,500 SEK + 25% VAT from June 1st, 2018

For selected finalists:

  • Complimentary access to NLSDays’ premises on September 10th only (including opening reception)
  • 25% discount on Small Company rate for those interested in attending the all-conference
  • 5,625 SEK + 25% VAT until May 31, 2018
  • 7,500 SEK + 25% VAT from June 1st, 2018

If you are interested in benefiting from the different registration discounts, please contact Jennie Ekbeck at Umeå Biotech Incubator to receive your discount code.

Hope to see you at the Startup Challenge @NLSDays 2018!

 Best wishes from Umeå Biotech Incubator – growing ideas that can change the world 

11 September 2018

+
DNB

Sponsored by:
DNB

View session Description
Life science financing – from seed to market

Super Session 1 – Financing

09:30 - 11:00Plenary Room - Level 5

Starting and evolving a company requires funds. This session is aimed at helping you better navigate the jungle of financing. We will take you through inspiring journeys that will be discussed by an experienced panel of investors, from Business Angels to Venture Capital firms.

Sobi

Sponsored by:
Sobi

View session Description
Patient engagement as a strategic imperative in medicines development- let’s look at the evidence on ‘return on engagement’

Super Session 2 – Return on Engagement

11:30 - 12:30Plenary Room - Level 5

Patient engagement in very much in vogue, but does it really make a difference and how can we measure this? This session will look at what patient engagement actually means in practical terms, and its impact as a business development tool, drawing on concrete good practice examples from the rare diseases community and personalised medicines.

We will also explore

  • European and international initiatives that are co-creating tools, metrics and resources to enable more structured and systematic patient engagement throughout the life cycle of medicines- specifically PARADIGM – a new Innovative Medicines Initiative Project, and PFMD, a global platform on patient engagement
  • Patient engagement strategies within various institutions, organisations and companies – and the kind of buy-in needed from different stakeholders involved to make patient engagement happen across the entire life cycle, at different decision-making points
  • The nexus between patient education in therapeutic innovation process and patient engagement
NanoMedNorth

Sponsored by:
NanoMedNorth

View session Description
Nano to Mega

Special Session – Nanomedicine

14:00 - 15:00Room 35-36

Visionary companies exploit nano-features to boost pharma- and medical device products. Scientific, financial and commercial perspectives of nanomedicine will be covered.

Moderator: Mr. Patrick Boisseau - Programme Manager on Nanomedicine, CEA-Leti

Sahlgrenska Science Park

Sponsored by:
Sahlgrenska Science Park

View session Description
What is the role of Digital Health in Pharma and Biotech?

Super Session 3 – Crossroads in BioPharma and HealthTech

14:00 - 15:00Plenary Room - Level 5

Technology gives access to a wealth of data and enables personalized care in an increasingly connected world. Future innovation in life science is about integrating medtech, pharmaceuticals and digital solutions. It requires innovative thinking in many dimensions.

How can we increase cooperation to integrate these areas more?

The regulatory requirements within pharma are challenging. The crusial question is how to handle the rapid development and take advantage of digital health solutions.

  • How can new technologies help improve compliance? What digital solutions will differentiate tomorrow’s drugs and change care?
  • How can digital development support and shorten the journey from idea to implemented service or product?
  • How should we drive the future’s innovation process so that digital solutions become an integrated part of the product development process? What drives traditional investors to invest digital health?
IQVIA
Servier CDMO

Hosted by:
IQVIA
Sponsored by:
Servier CDMO

View session Description
The Virtual Business Model in Drug Development – Challenges and Opportunities

Workshop 1 – Services Providers as Trusted Partners

15:15 - 16:15Room 35-36

Many SME companies focused on drug development choose to work according a virtual business model where key expertise is contracted ad hoc for specific tasks. Often also more general tasks such as project management may be covered by contracted staff. The virtual model is attractive because it adds flexibility and supports the agile organization. On the other hand, working virtually requires additional care when considering what tasks to outsource and criteria for selection of vendors.

The session “The Virtual Business Model” will focus on “WHY”, “WHEN” and “HOW” from a company management perspective. When will virtual competence add the extra edge are there situation when the virtual model is not advantageous?

The speaker list includes speakers experienced in working in a virtual business model as well as companies supplying virtual services.

View session Description
A precision approach is needed to master the complex changes required from the precision medicine opportunity

Super Session 4 – Precision Medicine

15:15 - 16:15Plenary Room - Level 5

Opportunities within precision and personalized medicine attracts much interest, not only from scientists, drug markers and patients but also from funders and decision makers.

Alongside opportunities, however, there are also several challenges to overcome to ensure successful launch and implementation of truly personalized therapies.

The changes required for drug manufacturers, healthcare providers and payers are radical and transformative, and involves the full value chain with all its stakeholders.

With its recent first-to-launch CAR-T therapy introduction in the US, Novartis is now preparing for launch of the therapy also in Europe.

This session will talk about what it will really take from the healthcare ecosystem players when preparing for taking full advantage of the promising new precision treatments currently being developed in many important disease areas.

Sweden Drug Delivery Industry Group
APL

Sponsored by:
Sweden Drug Delivery Industry Group
APL

View session Description
Ongoing Initiatives and Future Challenges

Super Session 5 – Drug Delivery of the Future

16:45 - 18:15Plenary Room - Level 5

Drug delivery is the science of getting the right amount of active drug to the right place in the body at the right time. The area of drug delivery has increased in importance as the medical needs continuously present new challenges to us and new and more complex treatment modalities are developed. In some of these modalities the drug delivery system and the active pharmaceutical ingredient (API) will be integrated to form the therapy and need to be fully aligned. Furthermore, challenges such as patient adherence, paediatrics/geriatrics and personalized medicine present challenges where innovative drug delivery solutions can add huge value to patients and society.

In this session, we will have presentations from three ongoing research initiatives related to advanced drug delivery: Sweden Drug Delivery Forum, NextBioForm and FoRmulaEx. We will also get a brief introduction to the industry network Sweden Drug Delivery Industry Group and get some messages from the sponsors of this session. Finally, a short panel discussion with the presenters discussing the future challenges and new opportunities will finish off the session.

City of Stockholm
Stockholms Stad
Invest Stockholm

Sponsored by:
City of Stockholm
Stockholms Stad
Invest Stockholm

12 September 2018

+
View session Description

Super Session 6 – International Investors Pitching

08:30 - 09:30Plenary Room - Level 5

Given you sometimes only get one chance to tell your story right, its essential that pitch it appropriately to investors. This session will provide an opportunity to hear from leading life science investors to better understand their areas of interest and investment criteria and what they would like to hear from you.

The pitching session will be followed by an interactive QA session to provide the audience with an opportunity to ask questions.

ReproUnion

Sponsored by:
ReproUnion

View session Description
Reproductive Medicine and New Business Opportunities

Super Session 7 – Reproductive Medicine

09:45 - 10:45Plenary Room - Level 5

This Super Session gathers top experts from the pharmaceutical and private fertility industry who will discuss the business and the industries perspective on reproductive medicine.

Every 12th child is conceived in a fertility clinic. 16-25 % of couples that try to get pregnant have fertility problems. The birth rate has fallen drastically over the past 50 years and most countries have fertility rate of less than 1,5 children per woman. The combination of demographic development and the low fertility rates demands new solutions and services. This development creates new business opportunities for the private fertility sector.

This session is hosted by ReproUnion – _a cross border collaboration between Sweden and Denmark within the area of reproductive medicine. The collaborative network consists of 14 clinical and research units within the Capital Region of Denmark, Region Zealand of Denmark and Region Skåne in Southern Sweden.

Speakers:
Dr. Stig Jørgensen - Program Director ReproUnion Dr. Rita Vassena - Scientific Director, Eugin, Executive Member of ESHRE Dr. Henk Jan Out - VP Reproductive Medicine & Women’s Health, Ferring Pharmaceuticals

Oslo Cancer Cluster

Sponsored by:
Oslo Cancer Cluster

View session Description
What is driving the next wave of innovation in Cancer Immunotherapy?

Super Session 8 – Catching the Immuno-Oncology wave!

11:15 - 12:45Plenary Room - Level 5

At this session, international experts from pharma, biotech, academia and the investment community will discuss how big data, personalized medicine, beyond the pill approaches, new targets, an increased understanding of the microbiome and insights from neuroscience could address these challenges and shape the next wave of innovation in Immuno-Oncology (I-O).

Over the past few years, the rapid development of novel cancer immunotherapy approaches has fundamentally disrupted the oncology space. I-O has not only become a key component of cancer therapy, but it has also reshaped priorities in oncology R&D across the industry, with unprecedented clinical success in certain cancer types continuing to fuel record investment and partnering activity. As of today, more than 2.000 I-O agents, including checkpoint-inhibitors, vaccines, oncolytic viruses and cellular therapies, are in preclinical or clinical development

Yet, still only a minority of patients benefits from effective and durable I-O treatments. Beyond resistance or unexplained lack of response, which could be addressed through a better understanding of optimal timing of therapy, better combination therapy design, or improved patient selection, a lack of novel targets and of an overall better understanding of specific immune mechanisms is becoming a roadblock to further advance in the space.

Moderator: Dr. Gaspar Taroncher-Oldenburg - Editor-at-Large, Nature Publishing Group

Speakers:
Dr. Richa Wilson - Associate Director, Digital and Personalized Healthcare, Roche Partnering Dr. Emilio Erazo-Fischer - Associate Director of Global Oncology BD, Boehringer Ingelheim Dr. Erica Sloan - Group Leader, Cancer & Neural-Immune Research Lab, Monash University Mr. Peter Benson - Co-founder and Managing Partner, Sunstone Life Science Ventures Dr. Simon Skjøde Jensen - CEO and Co-Founder, MonTa Biosciences

View session Description
The potential of health data and AI in personalized medicine

Super Session 9 – Artificial Intelligence in Life Science

14:00 - 15:30Plenary Room - Level 5

The fast growing amount of biobank and health data presents an unparalled opportunity for drug target and biomarker discovery, Real Worl Evidence-based research (RWE) and personalized healthcare.

However, this opportunity presents also a challenge on how to make sense of this data and find medically meaningful discoveries.

The application of artificial intelligence (AI) solutions may provide one answer to this medical needle in a hay stack problem and help us conquer the burder of common diseases such as diabetes, cancer and neurological diseases.